3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
13
Breast
9
Thoracic
7
Genitourinary
6
Gynecologic
4
CNS
4
Lymphoid
3
Other solid neoplasm
2
Dermatologic
2
Tumor-Agnostic
1
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Melanoma
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
157
Nivolumab
132
Ipilimumab
77
Cyclophosphamide
46
Specimen Handling
44
Magnetic Resonance Spectroscopy
39
cemiplimab
35
Biopsy
31
fludarabine
28
trametinib
24
relatlimab
24
binimetinib
23
Interleukin-2
21
fludarabine phosphate
20
dabrafenib
20
atezolizumab
20
Radiotherapy
20
Opdualag
19
Radiosurgery
18
CTLA-4 Antigen
18
encorafenib
17
aldesleukin
17
Blood Specimen Collection
17
avelumab
14
Immunoglobulin G
14
Disulfides
13
lenvatinib
11
Bevacizumab
11
lifileucel
10
Paclitaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Saline Solution
×
Dermatologic
×
1 year
×
Clear all
NCT03271372
2026-05-12
ADAM
University of Washington
Phase 3
Active not recruiting
101 enrolled
NCT05933577
2025-09-24
V940-001
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
1,089 enrolled